TeleClinic Journal
Articles on GLP-1 medications, metabolic health, and the science behind what we prescribe — written by our medical team.
Both medications are GLP-1 receptor agonists, but tirzepatide adds a second mechanism that produces greater average weight loss. We break down the clinical data.
Read article →
Tirzepatide's clinical trial results were unlike anything seen before in anti-obesity pharmacology. Here's what the data says — and what it doesn't.
Read article →
Nausea is the most common side effect of semaglutide and tirzepatide — but it's manageable. Our physicians share evidence-based strategies.
Read article →
GLP-1 medications significantly reduce appetite, but food choice still matters for nutrient density and tolerability. A practical guide.
Read article →
Subcutaneous injection feels intimidating before you've done it. After the first time, most patients find it takes under 30 seconds. Here's exactly how.
Read article →
NAD+ has become one of the most talked-about longevity interventions. We review the published evidence objectively.
Read article →